NOTTINGHAM, United Kingdom, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces the ...
Scancell to host presentation and Q&A on data at 13:00 BST NOTTINGHAM, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® ...
NOTTINGHAM, United Kingdom, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE ...
Scancell holds oral presentation of positive Phase 2 data on Immunobody ® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark in efficacy, durability, ...
British immunology firm Scancell has found a repeat buyer for its monoclonal antibodies. Genmab has plucked another anti-glycan antibody from Scancell’s shelves in a deal worth up to $630 million. The ...
PharmaJet’s intramuscular (IM) Needle-free Injection System - Stratis® - was used to deliver Scancell’s iSCIB1+ DNA immunotherapy in combination with immune checkpoint inhibitors in the SCOPE Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results